Home > News > Biophan Names John Lanzafame President of New Nanolution Division
September 16th, 2004
Biophan Names John Lanzafame President of New Nanolution Division
Biophan Technologies, Inc., a developer of next-generation biomedical technology, has appointed biotechnology executive John Lanzafame to serve as president of the Company's Nanolution division, according to Biophan CEO Michael Weiner.
As Nanolution president, Mr. Lanzafame will oversee Biophan's development of advanced nanotechnology-based drug delivery devices and drug-elution technologies, patents, and products.
Park Systems Announces Outsourced Analytical Services Including AFM Surface Imaging, Data Analysis and Interpretation September 30th, 2014
Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014
New Topical Hemostatic Agent: Neutral Self-Assembling Peptide Hydrogel September 30th, 2014
Chemical interactions between silver nanoparticles and thiols: A comparison of mercaptohexanol again September 30th, 2014
NREL Announces New Center Directors to lead R&D, Analysis Efforts September 30th, 2014
Jeff Andreson to Join Nanometrics as Chief Financial Officer September 4th, 2014
New Vice President Takes Helm at CNSE CMOST: Catherine Gilbert To Lead CNSE Children’s Museum of Science and Technology Through Expansion And Relocation August 29th, 2014
Nanometrics CFO to Resign for New Job Opportunity August 8th, 2014